Drugs targeting specific enzymes involved in histone modifications, such as HDAC inhibitors, HMT inhibitors, and BET inhibitors, are being developed and used to modify the epigenetic landscape of cancer cells, aiming to reverse malignant phenotypes. The gene discussed is HDAC9; the disease is cancer.